EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of CD19 CAR T‐Cell Therapy on Pathogen‐Specific Antibody Titers in Lymphoma Patients

Hayley Foy-Stones iD, Nicola Gardiner iD, Ellen Walsh, Derek G Doherty, Anthony M McElligott, Chris Armstrong, Nina Orfali iD, Robert Henderson, Elisabeth Vandenberghe, Elizabeth Higgins, Tor Hervig, Allison Waters iD und 4 weitere

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Hayley Foy-Stones und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Antigens, CD19, Antibodies, Viral, Antibodies, Bacterial, Lymphoma. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has exhibited efficacy in treating relapsed/refractory high‐grade B‐cell malignancies, but off‐tumor effects cause prolonged hypogammaglobulinemia and B‐cell aplasia. Limited data exist on pathogen‐specific IgG titers post‐CD19 CAR T‐cell therapy.

Methods

We evaluated the impact of CD19 CAR T‐cell therapy on vaccine‐preventable infectious disease IgG titers in 20 patients to assess humoral immunity. IgG titers for measles virus (MeV), mumps virus (MuV), rubella virus (RuV), varicella zoster virus (VZV), pneumococcal capsular polysaccharide, Haemophilus influenzae type B (Hib), and tetanus toxoid were measured at baseline and Day 100 post‐CD19 CAR T‐cell therapy.

Results

Seropositivity for all pathogens remained stable from baseline to Day 100. Quantitative IgG titers for MeV, MuV, RuV, VZV, and tetanus also remained stable. Median pneumococcal IgG and Hib IgG titers declined ( p < 0.05); however, no arbitrary fourfold decreases were observed. Median total IgG concentrations declined ( p < 0.05).

Conclusion

MeV, MuV, RuV, VZV, and tetanus toxoid IgG remained stable following CD19 CAR T‐cell therapy, while pneumococcal and Hib IgG titers showed marginal quantitative declines, without any fourfold reductions. Overall, humoral immunity at Day 100 following CD19 CAR T‐cell therapy remained largely preserved. These seroprevalence findings suggest that routine revaccination may not be required in our patient cohort and highlight the importance of patient monitoring to inform revaccination decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Antibodies, ViralAntibodies, BacterialLymphomaImmunotherapy, AdoptiveHumansFemaleImmunoglobulin GMaleMiddle AgedAdultTetanus ToxoidHerpesvirus 3, HumanMeasles virusImmunity, HumoralMumps virusRubella virusHaemophilus influenzae type bT-LymphocytesStreptococcus pneumoniaeAgedReceptors, Chimeric Antigen

Stichwörter der Autor:innen

CAR T‐cell therapyCD19Haemophilus influenzae type Blymphomameasles virusmumps viruspathogen antibody titerspneumococcal capsular polysacchariderubella virustetanus toxoidvaricella zoster virus

Substanzen

Immunoglobulin GAntigens, CD19Antibodies, ViralAntibodies, BacterialTetanus ToxoidReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland.
  • Trinity Translational Medicine Institute, Trinity College, Dublin, Ireland.
  • National Adult Stem Cell Transplant and Adult CAR T-Cell Programme, Haematology, St. James's Hospital, Dublin, Ireland.
  • Irish Blood Transfusion Service, Dublin, Ireland.
  • Department of Clinical Science, University of Bergen, Bergen, Norway.
  • UCD School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland.

ORCID-Profile: Hayley Foy-Stones, Nicola Gardiner, Nina Orfali, Allison Waters

Zitieren

APA

Foy-Stones, H., Gardiner, N., Walsh, E., Doherty, D. G., McElligott, A. M., Armstrong, C., Orfali, N., Henderson, R., Vandenberghe, E., Higgins, E., Hervig, T., Waters, A., Crowley, B., Groarke, E., Conlon, N. P., & Bacon, C. L. (2026). Impact of CD19 CAR T‐Cell Therapy on Pathogen‐Specific Antibody Titers in Lymphoma Patients. Transplant Infectious Disease. https://doi.org/10.1111/tid.70188

Vancouver

Foy-Stones H, Gardiner N, Walsh E, Doherty DG, McElligott AM, Armstrong C, et al. Impact of CD19 CAR T‐Cell Therapy on Pathogen‐Specific Antibody Titers in Lymphoma Patients. Transplant Infectious Disease. 2026. doi:10.1111/tid.70188

BibTeX
@article{FoyStones2026,
  author = {Foy-Stones, Hayley and Gardiner, Nicola and Walsh, Ellen and Doherty, Derek G and McElligott, Anthony M and Armstrong, Chris and Orfali, Nina and Henderson, Robert and Vandenberghe, Elisabeth and Higgins, Elizabeth and Hervig, Tor and Waters, Allison and Crowley, Brendan and Groarke, Elizabeth and Conlon, Niall P and Bacon, Christopher L},
  title = {Impact of CD19 CAR T‐Cell Therapy on Pathogen‐Specific Antibody Titers in Lymphoma Patients},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70188}
}
Kostenlos starten →